Personalized therapy in pain management: Where do we stand?

Pharmacogenomics

Volumn 11, Issue 6, 2010, Pages 843-864

  Stamer, Ulrike M ^a,b   Zhang, Lan ^a,b   Stüber, Frank ^b  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Analgesia; COMT; CYP; CYP2C9; CYP2D6; Cytochrome P450; Opioid receptor; OPRM1; Pain; Polymorphism

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; CATECHOL METHYLTRANSFERASE; CODEINE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DICLOFENAC; DIHYDROCODEINE; DRUG METABOLIZING ENZYME; HYDROCODONE; IBUPROFEN; METHADONE; MORPHINE; MU OPIATE RECEPTOR; MULTIDRUG RESISTANCE PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; OXYCODONE; PARACETAMOL; PAROXETINE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; CARRIER PROTEIN; CYTOCHROME P450; NARCOTIC ANALGESIC AGENT; OPIATE RECEPTOR;

ANALGESIC ACTIVITY; APNEA; AREA UNDER THE CURVE; BLEEDING; BRADYCARDIA; CANCER PAIN; CHRONIC PAIN; CYANOSIS; DEMETHYLATION; DEPRESSION; DNA POLYMORPHISM; DROWSINESS; DRUG EXCRETION; DRUG FATALITY; DRUG METABOLISM; DRUG SAFETY; DRUG TRANSFORMATION; EVENING DOSAGE; GASTROINTESTINAL HEMORRHAGE; GENE DUPLICATION; GENE EXPRESSION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GLUCURONIDATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; NEUROPATHIC PAIN; NONHUMAN; PAIN; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHENOTYPE; POSTOPERATIVE PAIN; RESPIRATION DEPRESSION; RESPIRATORY DISTRESS; REVIEW; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; GENETICS; METABOLISM; PHARMACOGENETICS; PROCEDURES;

ANALGESICS, OPIOID; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CARRIER PROTEINS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; INDIVIDUALIZED MEDICINE; PAIN; PHARMACOGENETICS; RECEPTORS, OPIOID;

EID: 77952908167     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.47     Document Type: Review

References (132)

1. Kehlet H, Jensen TS, Woolf CJ: Persistent postsurgical pain: risk factors and prevention. Lancet 367(9522), 1618-1625 (2006).
2. Katz J, Seltzer Z: Transition from acute to chronic postsurgical pain: risk factors and protective factors. Expert Rev. Neurother. 9(5), 723-744 (2009).
3. Skorpen F, Laugsand EA, Klepstad P et al.: Variable response to opioid treatment: any genetic predictors within sight? Palliat. Med. 22, 310-327 (2008).
4. Lötsch J, Geisslinger G, Tegeder I: Genetic modulation of the pharmacological treatment of pain. Pharmacol Ther. 124(2), 168-184 (2009).
5. Rollason V, Samer C, Piguet V, Dayer P, Desmeules J: Pharmacogenetics of analgesics: toward the individualization of prescription. Pharmacogenomics 9(7), 905-933 (2008).
6. Smith HS: Variations in opioid responsiveness. Pain Physician 11, 237-248 (2008).
7. Shah RR: Pharmacogenetics in drug regulation: promise, potential and pitfalls. Philos. Trans. R. Soc. Lond. B Biol. Sci. 360(1460), 1617-1638 (2005).
8. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C: Infuence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther. 116(3), 496-526 (2007).
9. Eichelbaum M, Ingelman-Sundberg M, Evans WE: Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 57, 119-137 (2006).
10. Wang B, Yang LP, Zhang XZ, Huang SQ, Bartlam M, Zhou SF: New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. Drug Metab. Rev. 41(4), 573-643 (2009).
11. Daly AK, Brockmoller J, Broly F et al.: Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6(3), 193-201 (1996).
12. Zhou SF: Polymorphism of human cytochrome P450 2D6 and its clinical signifcance: part I. Clin. Pharmacokinet. 48(11), 689-723 (2009).
13. Maddocks I, Somogyi A, Abbott F, Hayball P, Parker D: Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. J. Pain Symptom Manage. 12, 182-189 (1996).
14. Gasche Y, Daali Y, Fathi M et al.: Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N. Engl. J. Med. 351(27), 2827-2831 (2004).
15. Susce MT, Murray-Carmichael E, de Leon J: Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Prog. Neuropsychopharmacol. Biol. Psychiatry 30(7), 1356-1358 (2006).
16. Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ: Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 368(9536), 704 (2006).
17. Zhou SF: Polymorphism of human cytochrome P450 2D6 and its clinical signifcance: part II. Clin. Pharmacokinet. 48(12), 761-804 (2009).
18. Williams DG, Hatch DJ, Howard RF: Codeine phosphate in paediatric medicine. Br. J. Anaesth. 86(3), 413-421 (2001).
19. Thorn CF, Klein TE, Altman RB. Codeine and morphine pathway. Pharmacogenet. Genomics 19(7), 556-558 (2009).
20. Lötsch J, Geisslinger G, Tegeder I. Genetic modulation of the pharmacological treatment of pain. Pharmacol. Ther. 124(2), 168-184 (2009).
21. Poulsen L, Brosen K, Arendt-Nielsen L, Gram LF, Elbaek K, Sindrup SH: Codeine and morphine in extensive and poor metabolisers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur. J. Clin. Pharmacol. 51(3-4), 289-295 (1996).
22. Persson K, Sjöström S, Sigurdardottir I et al.: Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in ten extensive metabolisers and one poor metaboliser of dextromethorphan. Br. J. Clin. Pharmacol. 39(2), 182-186 (1995).
23. Williams DG, Patel A, Howard RF: Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability. Br. J. Anaesth. 89(6), 839-845 (2002).
24. Kirchheiner J, Schmidt H, Tzvetkov M et al.: Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolisers due to CYP2D6 duplication. Pharmacogenomics J. 7(4), 257-265 (2007).
25. Lötsch J, Rohrbacher M, Schmidt H, Doehring A, Brockmöller J, Geisslinger G: Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation? Pain 144(1-2), 119-124 (2009).
26. Ciszkowski C, Madadi P, Phillips MS, Lauwers AE, Koren G: Codeine, ultrarapid-metabolism genotype, and postoperative death. N. Engl. J. Med. 361(8), 827-828 (2009).
27. Voronov P, Przybylo HJ, Jagannathan N: Apnea in a child after oral codeine: a genetic variant-an ultra-rapid metabolizer. Paediatr. Anaesth. 17(7), 684-887 (2007).
28. Madadi P, Koren G, Cairns J et al.: Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Can. Fam. Physician 53(1), 33-35 (2007).
29. Madadi P, Shirazi F, Walter FG, Koren G: Establishing causality of CNS depression in breastfed infants following maternal codeine use. Paediatr. Drugs 10(6), 399-404 (2008).
30. Madadi P, Ross CJ, Hayden MR et al.: Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin. Pharmacol. Ther. 85(1), 31-35 (2009).
31. Fromm MF, Hofmann U, Griese EU, Mikus G: Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans. Clin. Pharmacol. Ther. 58(4), 374-382 (1995).
32. Wilder-Smith CH, Hufschmid E, Thormann W: The visceral and somatic antinociceptive effects of dihydrocodeine and its metabolite, dihydromorphine. A cross-over study with extensive and quinidine-induced poor metabolizers. Br. J. Clin. Pharmacol. 45(6), 575-581 (1998).
33. Schmidt H, Vormfelde SV, Walchner-Bonjean M et al.: The role of active metabolites in dihydrocodeine effects. Int. J. Clin. Pharmacol. Ther. 41(3), 95-106 (2003).
34. Otton SV, Schadel M, Cheung SW et al.: CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin. Pharmacol. Ther. 54(5), 463-472 (1993).
35. Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA: CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br. J. Clin. Pharmacol. 57(3), 287-297 (2004).
36. Kaplan HL, Busto UE, Baylon GJ et al.: Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability. J. Pharmacol. Exp. Ther. 281(1), 103-108 (1997).
37. Scott LJ, Perry CM: Tramadol: a review of its use in perioperative pain. Drugs 60(1), 139-176 (2000).
38. Lai J, Ma SW, Porreca F, Raffa RB: Tramadol, M1 metabolite and enantiomer affnities for cloned human opioid receptors expressed in transfected HN9.10 neuroblastoma cells. Eur. J. Pharmacol. 316(2-3), 369-372 (1996).
39. Enggaard TP, Poulsen L, Arendt-Nielsen L, Brøsen K, Ossig J, Sindrup SH: The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. Anesth. Analg. 102(1), 146-150 (2006).
40. Stamer UM, Lehnen K, Höthker F et al.: Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 105(1-2), 231-238 (2003).
41. Wang G, Zhang H, He F, Fang X: Effect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population. Eur. J. Clin. Pharmacol. 62(11), 927-931 (2006).
42. Pedersen RS, Damkier P, Brøsen K: Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers. Eur. J. Clin. Pharmacol. 62(7), 513-521 (2006).
43. Stamer UM, Musshoff F, Kobilay M, Madea B, Hoeft A, Stüber F: Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Clin. Pharmacol. Ther. 82(1), 41-47 (2007).
44. García-Quetglas E, Azanza JR, Sádaba B, Muñoz MJ, Gil I, Campanero MA: Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype. Pharmacol. Res. 55(2), 122-130 (2007).
45. Kirchheiner J, Keulen JT, Bauer S, Roots I, Brockmöller J: Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. J. Clin. Psychopharmacol. 28(1), 78-83 (2008).
46. Stamer UM, Stüber F, Muders T, Musshoff F: Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. Anesth. Analg. 107(3), 926-929 (2008).
47. Lalovic B, Kharash E, Hoffer C, Risler L, Liu-Chen LY, Shen DD: Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating metabolites. Clin. Pharmacol. Ther. 79(5), 461-479 (2006).
48. Lemberg KK, Heiskanen TE, Neuvonen M et al.: Does co-administration of paroxetine change oxycodone analgesia: an interaction study in chronic pain patients. Scandinavian J. Pain 1, 24-33 (2010).
49. Zwisler ST, Enggaard TP, Mikkelsen S, Brosen K, Sindrup SH: Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia. Acta Anaesthesiol. Scand. 54(2), 232-240 (2010).
50. Zwisler ST, Enggaard TP, Noehr-Jensen L et al.: The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. Basic Clin. Pharmacol. Toxicol. 104(4), 335-344 (2009).
51. Nieminen TH, Hagelberg NM, Saari TI et al.: Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. Anesthesiology 110(6), 1371-1378 (2009).
52. Shaiova L, Berger A, Blinderman CD et al.: Consensus guideline on parenteral methadone use in pain and palliative care. Palliat. Support. Care 6(2), 165-176 (2008).
53. Bruera E, Sweeney C: Methadone use in cancer patients with pain: a review. J. Palliat. Med. 5(1), 127-138 (2002).
54. Crettol S, Déglon JJ, Besson J et al.: ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin. Pharmacol. Ther. 80(6), 668-681 (2006).
55. Lötsch J, Skarke C, Wieting J et al.: Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin. Pharmacol. Ther. 79(1), 72-89 (2006).
56. de los Cobos J, Valero S, Haro G et al.: Development and psychometric properties of the Verona Service Satisfaction Scale for methadone-treated opioid-dependent patients (VSSS-MT). Drug Alcohol Depend. 68(2), 209-214 (2002).
57. Coller JK, Joergensen C, Foster DJ et al.: Lack of infuence of CYP2D6 genotype on the clearance of (R)-, (S)-and racemic-methadone. Int. J. Clin. Pharmacol. Ther. 45(7), 410-417 (2007).
58. Kirchheiner J, Nickchen K, Bauer M et al.: Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 9(5), 442-473 (2004).
59. Steimer W, Zöpf K, von Amelunxen S et al.: Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifes patients with low or high risk for side effects in amitriptyline therapy. Clin. Chem. 51(2), 376-385 (2005).
60. Zhou SF, Zhou ZW, Huang M: Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology (2009) (Epub ahead of print).
61. Kirchheiner J, Brockmöller J: Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther. 77(1), 1-16 (2005).
62. Rodrigues AD: Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab. Dispos. 33(11), 1567-1575 (2005).
63. Kirchheiner J, Störmer E, Meisel C, Steinbach N, Roots I, Brockmoller J: Infuence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. Pharmacogenetics 13(8), 473-480 (2003).
64. Pilotto A, Seripa D, Franceschi M et al.: Genetic susceptibility to nonsteroidal anti-infammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology 133(2), 465-471 (2007).
65. Dorado P, Berecz R, Norberto MJ et al.: CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. Eur. J. Clin. Pharmacol. 59(3), 221-225 (2003).
66. Tang C, Shou M, Rushmore TH et al.: In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics. Pharmacogenetics 11(3), 223-235 (2001).
67. Kirchheiner J, Meineke I, Freytag G, Meisel C, Roots I, Brockmoller J: Enantiospecifc effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. Clin. Pharmacol. Ther. 72(1), 62-75 (2002).
68. Martínez C, García-Martín E, Blanco G, Gamito FJ, Ladero JM, Agúndez JA: The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. Br. J. Clin. Pharmacol. 59(1), 62-69 (2005).
69. García-Martín E, Martínez C, Tabarés B, Frías J, Agúndez JA: Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin. Pharmacol. Ther. 76(2), 119-127 (2004).
70. Vianna-Jorge R, Perini JA, Rondinelli E, Suarez-Kurtz G: CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. Clin. Pharmacol. Ther. 76(1), 18-26 (2004).
71. Peiró AM, Novalbos J, Zapater P et al.: Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards. Pharmacol. Res. 59(1), 62-68 (2009).
72. Perini JA, Vianna-Jorge R, Brogliato AR, Suarez-Kurtz G: Infuence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam. Clin. Pharmacol. Ther. 78(4), 362-369 (2005).
73. Guo Y, Zhang Y, Wang Y et al.: Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans. Drug Metab. Dispos. 33(6), 749-753 (2005).
74. Liu YL, Zhang W, Tan ZR et al.: Effect of the CYP2C9*3 allele on lornoxicam metabolism. Clin. Chim. Acta 364(1-2), 287-291 (2006).
75. Dorado P, Cavaco I, Cáceres MC, Piedade R, Ribeiro V, Llerena A: Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers. Eur. J. Clin. Pharmacol. 64(10), 967-970 (2008).
76. Daily EB, Aquilante CL: Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics 10(9), 1489-1510 (2009).
77. Visser LE, van Vliet M, van Schaik RH et al.: The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics 14(1), 27-33 (2004).
78. Pilotto A, Franceschi M, Vitale DF et al.: Upper gastrointestinal symptoms and therapies in elderly out-patients, users of non-selective NSAIDs or coxibs. Aliment. Pharmacol. Ther. 22(2), 147-155 (2005).
79. Blanco G, Martínez C, Ladero JM: Interaction of CYP2C8 and CYP2C9 genotypes modifes the risk for nonsteroidal anti-infammatory drugs-related acute gastrointestinal bleeding. Pharmacogenet. Genomics 18(1), 37-43 (2008).
80. Vonkeman HE, van de Laar MA, van der Palen J, Brouwers JR, Vermes I: Allele variants of the cytochrome P450 2C9 genotype in white subjects from The Netherlands with serious gastroduodenal ulcers attributable to the use of NSAIDs. Clin. Ther. 28(10), 1670-1676 (2006).
81. Ma J, Yang XY, Qiao L, Liang LQ, Chen MH: CYP2C9 polymorphism in non-steroidal anti-infammatory drugs-induced gastropathy. J. Dig. Dis. 9(2), 79-83 (2008).
82. Agúndez JA, García-Martín E, Martínez C: Genetically based impairment in CYP2C8-and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin. Drug Metab. Toxicol. 5(6), 607-620 (2009).
83. Harder S, Thürmann P: Clinically important drug interactions with anticoagulants. An update. Clin. Pharmacokinet. 30(6), 416-444 (1996).
84. Visser LE, van Schaik RH, van Vliet M et al.: Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-infammatory drugs and coumarin anticoagulants. Clin. Pharmacol. Ther. 77(6), 479-485 (2005).
85. Park HJ, Shinn HK, Ryu SH, Lee HS, Park CS, Kang JH: Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans. Clin. Pharmacol. Ther. 81(4), 539-546 (2007).
86. Zwisler ST, Enggaard TP, Noehr-Jensen L et al.: The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes. Fundam. Clin. Pharmacol. (2009) (Epub ahead of print).
87. Campa D, Gioia A, Tomei A, Poli P, Barale R: Association of ABCB1/MDR1 and OPR M1 gene polymorphisms with morphine pain relief. Clin. Pharmacol. Ther. 83(4), 559-566 (2008).
88. Lötsch J, von Hentig N, Freynhagen R et al.: Cross-sectional analysis of the infuence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet. Genomics 19(6), 429-436 (2009).
89. Levran O, O'Hara K, Peles E et al.: ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum. Mol. Genet. 17(14), 2219-2227 (2008).
90. Coller JK, Barratt DT, Dahlen K, Loennechen MH, Somogyi AA: ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin. Pharmacol. Ther. 80(6), 682-690 (2006).
91. Crettol S, Déglon JJ, Besson J et al.: No infuence of ABCB1 haplotypes on methadone dosage requirement. Clin. Pharmacol. Ther. 83(5), 668-669 (2008).
92. Lee YS, Kim H, Wu TX, Wang XM, Dionne RA: Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs. Clin. Pharmacol. Ther. 79(5), 407-418 (2006).
93. Skarke C, Reus M, Schmidt R et al.: The cyclooxygenase 2 genetic variant-765G>C does not modulate the effects of celecoxib on prostaglandin E2 production. Clin. Pharmacol. Ther. 80(6), 621-632 (2006).
94. Ono T, Muto A, Kaneda T, Arita E, Yoshida T: Novel linkage disequilibrium of single nucleotide polymorphisms in the transcriptional regulatory region of micro-opioid receptor gene in Japanese population. Biol. Pharm. Bull. 32(4), 721-773 (2009).
95. Chou WY, Yang LC, Lu HF et al.: Association of μ-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol. Scand. 50(7), 787-792 (2006).
96. Chou WY, Wang CH, Liu PH, Liu CC, Tseng CC, Jawan B: Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology 105(2), 334-337 (2006).
97. Oertel BG, Kettner M, Scholich K et al.: A common human micro-opioid receptor genetic variant diminishes the receptor signaling effcacy in brain regions processing the sensory information of pain. J. Biol. Chem. 284(10), 6530-6535 (2009).
98. Klepstad P, Rakvag TT, Kaasa S et al.: The 118 A > G polymorphism in the human μ-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol. Scand. 48(10), 1232-1239 (2004).
99. Walter C, Lötsch J: Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. Pain 146(3), 270-275 (2009).
100. Janicki PK, Schuler G, Francis D et al.: A genetic association study of the functional A118G polymorphism of the human μ-opioid receptor gene in patients with acute and chronic pain. Anesth. Analg. 103(4), 1011-1017 (2006).
101. Coulbault L, Beaussier M, Verstuyft C et al.: Environmental and genetic factors associated with morphine response in the postoperative period. Clin. Pharmacol. Ther. 79(4), 316-324 (2006).
102. Huehne K, Leis S, Muenster T et al.: High post surgical opioid requirements in Crohn's disease are not due to a general change in pain sensitivity. Eur. J. Pain 13(10), 1036-1042 (2009).
103. Landau R, Kern C, Columb MO, Smiley RM, Blouin JL: Genetic variability of the mu-opioid receptor infuences intrathecal fentanyl analgesia requirements in laboring women. Pain 139(1), 5-14 (2008).
104. Landau R: One size does not ft all: genetic variability of μ-opioid receptor and postoperative morphine consumption. Anesthesiology 105(2), 235-237 (2006).
105. Lötsch J. Basic genetic statistics are necessary in studies of functional association in anesthesiology. Anesthesiology 107, 168-169 (2007).
106. Chanock SJ, Manolio T, Boehnke M et al.; NCI-NHGRI Working Group on Replication in Association Studies: Replicating genotype-phenotype associations. Nature 447(7145), 655-660 (2007).
107. Zubieta JK, Heitzeg MM, Smith YR et al.: Val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 299(5610), 1240-1243 (2003).
108. Rakvåg TT, Klepstad P, Baar C et al.: The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may infuence morphine requirements in cancer pain patients. Pain 116(1-2), 73-78 (2005).
109. Reyes-Gibby CC, Shete S, Rakvåg T et al.: Exploring joint effects of genes and the clinical effcacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 130(1-2), 25-30 (2007).
110. Kim H, Neubert JK, San Miguel A et al.: Genetic infuence on variability in human acute experimental pain sensitivity associated with gender, ethnicity and psychological temperament. Pain 109(3), 488-496 (2004).
111. Kim H, Lee H, Rowan J, Brahim J, Dionne RA: Genetic polymorphisms in monoamine neurotransmitter systems show only weak association with acute post-surgical pain in humans. Mol. Pain. 18(2), 24 (2006).
112. Birklein F, Depmeier C, Rolke R et al.: A family-based investigation of cold pain tolerance. Pain 138(1), 111-118 (2008).
113. Rakvåg TT, Ross JR, Sato H, Skorpen F, Kaasa S, Klepstad P: Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with pain. Mol. Pain. 18(4), 64 (2008).
114. Ross JR, Riley J, Taegetmeyer AB et al.: Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects. Cancer 112(6), 1390-1403 (2008).
115. Lacroix-Fralish ML, Mogil JS. Progress in genetic studies of pain and analgesia. Annu. Rev. Pharmacol. Toxicol. 49, 97-121 (2009).
116. Kim H, Clark D, Dionne RA: Genetic contributions to clinical pain and analgesia: avoiding pitfalls in genetic research. J. Pain 10(7), 663-693 (2009).
117. Lötsch J, Flühr K, Neddermayer T, Doehring A, Geisslinger G: The consequence of concomitantly present functional genetic variants for the identifcation of functional genotype-phenotype associations in pain. Clin. Pharmacol. Ther. 85(1), 25-30 (2009).
118. Kim H, Ramsay E, Lee H, Wahl S, Dionne RA: Genome-wide association study of acute post-surgical pain in humans. Pharmacogenomics 10(2), 171-179 (2009).
119. Tegeder I, Lötsch J: Current evidence for a modulation of low back pain by human genetic variants. J. Cell Mol. Med. (2009) (Epub ahead of print).
120. Somogyi AA, Barratt DT, Coller JK: Pharmacogenetics of opioids. Clin. Pharmacol. Ther. 81(3), 429-444 (2007).
121. Slade GD, Diatchenko L, Bhalang K et al.: Infuence of psychological factors on risk of temporomandibular disorders. J. Dent. Res. 86(11), 1120-1125 (2007).
122. George SZ, Wallace MR, Wright TW et al.: Evidence for a biopsychosocial infuence on shoulder pain: pain catastrophizing and catechol-O-methyltransferase (COMT) diplotype predict clinical pain ratings. Pain 136(1-2), 53-61 (2008).
123. Hapgood R: The potential and limitations of personalized medicine in the doctor-patient relationship. Pharmacogenomics 4(6), 685-687 (2003). (Pubitemid 37428355)
124. López-Rodríguez R, Novalbos J, Gallego-Sandín S et al.: Infuence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers. Pharmacol. Res. 58(1), 77-84 (2008).
125. Bae J W, Kim JH, Choi CI et al: Effect of CYP2C9*3 allele on the pharmacokinetics of naproxen in Korean subjects. Arch. Pharm. Res. 32(2), 269-273 (2009).
126. Huang CJ, Liu HF, Su NY et al.: Association between human opioid receptor genes polymorphisms and pressure pain sensitivity in females. Anaesthesia 63(12), 1288-1295 (2008).
127. Sia AT, Lim Y, Lim EC et al.: A118G single nucleotide polymorphism of human μ-opioid receptor gene infuences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology 109(3), 520-526 (2008).
128. Hayashida M, Nagashima M, Satoh Y et al.: Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype. Pharmacogenomics 9(11), 1605-1616 (2008).
129. Fukuda K, Hayashida M, Ide S et al.: Association between OPRM1 gene polymorphisms and fentanyl sensitivity in patients undergoing painful cosmetic surgery. Pain 147(1-3), 194-201 (2009).
130. Tan EC, Lim EC, Teo YY, Lim Y, Law HY, Sia AT: Ethnicity and OPRM variant independently predict pain perception and patient-controlled analgesia usage for post-operative pain. Mol. Pain. 23(5), 32 (2009).
131. Wu WD, Wang Y, Fang YM, Zhou HY: Polymorphism of the mu-opioid receptor gene (OPRM1 118A>G) affects fentanyl-induced analgesia during anesthesia and recovery. Mol. Diagn. Ther. 13(5), 331-337 (2009).
132. Ginosar Y, Davidson EM, Meroz Y, Blotnick S, Shacham M, Caraco Y: Mu-opioid receptor (A118G) single-nucleotide polymorphism affects alfentanil requirements for extracorporeal shock wave lithotripsy: a pharmacokinetic- pharmacodynamic study. Br. J. Anaesth. 103(3), 420-427 (2009).